Critical Choices In Financing The Response To The Global HIV/AIDS Pandemic

Abstract

ABSTRACT:The AIDS pandemic will enter its fiftieth year in 2031. Despite much progress, there are thirty-three million infected people worldwide, and 2.3 million adults were newly infected in 2007. Without a change in approach, a major pandemic will still be with us in 2031. Modeling carried out for the AIDS 2031 project suggests that funding required for developing countries to address the pandemic could reach $35 billion annually by 2031-three times the current level. Even then, more than a million people will still be newly infected each year. However, wise policy choices focusing on high-impact prevention and efficient treatment could cut costs by half. Investments in new prevention tools and major behavior-change efforts are needed to spur more rapid advances. Existing donors, middleincome countries with contained epidemics, philanthropists, and innovative financing could help bridge the likely funding gap. [Health Aff (Millwood). 2009;28(6):1591-605]

HIV Treatment Cascades that Leak: Correlates of Drop-off from the HIV Care Continuum among Men who have Sex with Men Worldwide

“…Drop-off may be linked to inequities in access to HIV services that are in-turn driven by the relative lack of resources and social disenfranchisement [25,26]. Resource constrained countries may be investing less in their health infrastructures [27]. However, poorer countries are more likely to receive international funds to support their HIV response than middle income countries [28] This may explain why in our study MSM in lower income countries were more likely to have tested for HIV.…”

Application of magnetic field hyperthermia and superparamagnetic iron oxide nanoparticles to HIV-1-specific T-cell cytotoxicity

“…[5][6][7][8][9][10][11] Patients must therefore have lifelong HAART, which is expensive and currently undeliverable to all who need it, especially in less industrialized regions, such as sub-Saharan Africa. 12 Novel strategies need to be developed if HIV is to be eradicated.…”

Characterisation, Evaluation and Clinical Significance of Latent HIV-1 Reservoirs and Therapeutic Strategies for HIV Eradication

“…There is also morbidity in patients on HAART that is not explained by drug toxicities, mostly due to cardiovascular and metabolic complications [29][30], as well as renal and hepatic toxicities, osteoporosis, dementia and ageing [31]. Also, the logistics of providing HAART to developing regions are currently extremely challenging [32]. Collectively, these data show that HAART mediated eradication of HIV is unlikely and that there is a real need for new therapies if the goal of HIV eradication is ever to be achieved.…”